According to a recent LinkedIn post from Cagent Vascular Inc, vascular surgeon Dr. Edward Gifford of Hartford HealthCare reportedly used the company’s Serranator device in two sizes to treat a complex peroneal-through-plantar arterial occlusion. The post notes use of low inflation pressures, controlled luminal gain, and restoration of blood flow to the foot in this #CaseoftheWeek example.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post also points to a newly published study in the Journal of Endovascular Therapy, described as the largest series to date of a specialty balloon in inframalleolar vessels, with 89.9% of wounds healed or improved at six months. For investors, this type of clinical evidence and real-world case visibility may support physician adoption, strengthen reimbursement and clinical guidelines positioning, and potentially enhance Cagent Vascular’s competitive profile in limb-salvage and endovascular therapy markets.